Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Pier Luca D'Alessandro"'
Autor:
Laura Tandeske, Claudio R. Thoma, Elizabeth R. Sprague, Scott M. Brittain, Lynn M. McGregor, Edward P. Harvey, Pier Luca D’Alessandro, Markus Schirle, Dustin Dovala, Dennis L. Buckley, Zachary J. Hauseman, Scott Gleim, Benika J. Pinch, William C. Forrester
Targeted protein degradation is a rapidly developing therapeutic modality that promises lower dosing and enhanced selectivity as compared to traditional occupancy-driven inhibitors, and the potential to modulate historically intractable targets. Whil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::228bf26e4d8c7058504d63e85228d26a
https://doi.org/10.1101/2020.08.13.249482
https://doi.org/10.1101/2020.08.13.249482
Autor:
Dustin Dovala, Markus Schirle, Elizabeth R. Sprague, Zachary J. Hauseman, Lei Xu, Scott Gleim, Dennis L. Buckley, Laura Tandeske, William C. Forrester, Scott M. Brittain, Pier Luca D’Alessandro, Benika J. Pinch, Lynn M. McGregor, Edward P. Harvey, Claudio R. Thoma, Jennifer Lipps
Publikováno v:
Cell Chemical Biology. 29:57-66.e6
Targeted protein degradation is a rapidly developing therapeutic modality that promises lower dosing and enhanced selectivity as compared to traditional occupancy-driven inhibitors, and the potential to modulate historically intractable targets. Whil
Autor:
Thomas Vorherr, Rudolf Griss, Kui-Thong Tan, Pier Luca D’Alessandro, Ruud Hovius, Kai Johnsson, Silvia Scarabelli
Publikováno v:
Journal of the American Chemical Society
We are introducing a new approach to evaluate cellular uptake of drugs and drug candidates into living cells. The approach is based on converting the protein target of a given class of compounds into a fluorescent biosensor. By measuring the binding
Autor:
Hacer Karatas, Gregory Hollingworth, Pier Luca D’Alessandro, Elena A. Goun, Aleksey Yevtodiyenko, Tamara Maric, Thomas Vorherr
Publikováno v:
ACS Chemical Biology.
Peptides constitute an important class of drugs for the treatment of multiple metabolic, oncological, and neurodegenerative diseases, and several hundred novel therapeutic peptides are currently in the preclinical and clinical stages of development.
Autor:
Hacer, Karatas, Tamara, Maric, Pier Luca, D'Alessandro, Aleksey, Yevtodiyenko, Thomas, Vorherr, Gregory J, Hollingworth, Elena A, Goun
Publikováno v:
ACS chemical biology. 14(10)
Peptides constitute an important class of drugs for the treatment of multiple metabolic, oncological, and neurodegenerative diseases, and several hundred novel therapeutic peptides are currently in the preclinical and clinical stages of development.
Autor:
Markus Kaufmann, Frédéric Baysang, Amanda Cobos-Correa, Pascal Furet, Therese-Marie Stachyra, Andreas Marzinzik, Nicole Buschmann, Pier Luca D’Alessandro, Johannes Ottl, Dimitrios Lizos, Reto Brunner, Thomas Vorherr
Publikováno v:
Angewandte Chemie International Edition. 55:16026-16030
To study the behavior of MDM2-p53 inhibitors in a disease-relevant cellular model, we have developed and validated a set of bioorthogonal probes that can be fluorescently labeled in cells and used in high-content screening assays. By using automated